TILsOV
Phase NA Terminated
36 enrolled
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase 1 Terminated
18 enrolled 19 charts
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
Terminated
22 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Phase 2/3 Terminated
600 enrolled
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Phase 1 Terminated
58 enrolled
ARTISTRY-7
Phase 3 Terminated
456 enrolled 19 charts
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 1 Terminated
1 enrolled 5 charts
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
START
Terminated
10 enrolled
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Terminated
12 enrolled 13 charts
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Terminated
1 enrolled 5 charts